Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, has announced the launch of the PrepQuant™ System, an automated sample preparation platform designed to standardize and simplify pre-analytical workflows in molecular diagnostics.
This system was developed in collaboration with Hitachi High-Tech Corporation. The PrepQuant System integrates nucleic acid extraction, concentration, and quantification into a single automated instrument. The platform aims to address a key bottleneck in molecular testing by reducing variability, improving consistency, and lowering operational costs associated with multi-step sample preparation processes.
The system is assay-agnostic and capable of generating highly concentrated genomic DNA and cell-free DNA (cfDNA) suitable for downstream applications such as next-generation sequencing (NGS), quantitative PCR (qPCR), and digital PCR (dPCR). By consolidating traditionally separate workflows, the PrepQuant System minimizes manual intervention, reduces laboratory footprint, and enhances overall testing efficiency.
According to Jeff Miller, CEO and CSO of Invivoscribe, the system represents a critical step toward standardizing the full diagnostic workflow. He emphasized that consistency in sample preparation is essential in precision medicine, particularly for MRD assessment and liquid biopsy applications, where test accuracy is highly dependent on input material quality.
The development of the PrepQuant System was informed by operational insights from LabPMM, Invivoscribe’s global network of clinical laboratories. Jordan Thornes, Vice President of Global Clinical Laboratory Operations, noted that existing workflows often require multiple instruments and protocols, increasing labor demands and the risk of error. The new platform is designed to address these challenges by delivering a unified, automated solution.
The PrepQuant System has been validated for use with blood, plasma, and bone marrow samples, with additional specimen types currently under development. Invivoscribe plans to officially unveil the system at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place from April 19–22 in San Diego.
Commercial rollout is expected to begin in North America in August 2026, followed by European availability in January 2027. The company also anticipates launching additional assay kits by the end of 2026 to expand the system’s applications across a broader range of molecular testing use cases.
